Neurology Central

European Commission approves first immunotherapy for high-risk neuroblastoma patients

The European Commission has approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients.
To view restricted content, please:

Leave A Comment